Kezar Life Sciences (NASDAQ:KZR – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.
Valuation and Earnings
This table compares Kezar Life Sciences and Tectonic Therapeutic”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kezar Life Sciences | N/A | N/A | -$56.03 million | ($6.17) | -1.18 |
| Tectonic Therapeutic | N/A | N/A | -$74.15 million | ($4.46) | -6.25 |
Analyst Ratings
This is a summary of recent ratings for Kezar Life Sciences and Tectonic Therapeutic, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kezar Life Sciences | 2 | 4 | 0 | 0 | 1.67 |
| Tectonic Therapeutic | 1 | 0 | 5 | 1 | 2.86 |
Kezar Life Sciences currently has a consensus price target of $6.00, indicating a potential downside of 17.70%. Tectonic Therapeutic has a consensus price target of $79.83, indicating a potential upside of 186.24%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Kezar Life Sciences.
Profitability
This table compares Kezar Life Sciences and Tectonic Therapeutic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kezar Life Sciences | N/A | -55.42% | -47.87% |
| Tectonic Therapeutic | N/A | -32.33% | -30.92% |
Institutional and Insider Ownership
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Kezar Life Sciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.27, suggesting that its share price is 227% more volatile than the S&P 500.
Summary
Tectonic Therapeutic beats Kezar Life Sciences on 9 of the 12 factors compared between the two stocks.
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
